Understanding how a specific receptor affects breast cancer treatment
Investigating the Roles of Pregnane X Receptor in Human Breast Cancers
This study is looking at how a specific protein called PXR affects breast cancer and how it might make some treatments less effective, with the hope of finding better ways to help patients respond to chemotherapy.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kansas City University NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10794789 on NIH RePORTER |
What this research studies
This research investigates the role of the Pregnane X Receptor (PXR) in breast cancer, particularly how it influences drug metabolism and resistance to chemotherapy. By examining human breast cancer cell lines, the researchers aim to uncover how PXR activation affects gene expression and cellular behavior, which could lead to improved treatment strategies. The study focuses on the metabolic pathways regulated by PXR and how these pathways contribute to the challenges of chemotherapy resistance. Ultimately, the goal is to enhance patient outcomes by tailoring treatments based on PXR's activity.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with breast cancer who are experiencing challenges with chemotherapy effectiveness.
Not a fit: Patients with non-breast cancer diagnoses or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective breast cancer treatments that overcome drug resistance.
How similar studies have performed: Previous research has shown promising results in understanding the role of drug metabolism in cancer treatment, suggesting that this approach could yield valuable insights.
Where this research is happening
Kansas City, United States
- Kansas City University — Kansas City, United States (Active)
Researchers
- Principal investigator: Creamer, Bradley Allen — Kansas City University
- Study coordinator: Creamer, Bradley Allen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.